Injexate (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the formation of tetrahydrofolate needed for DNA and RNA synthesis. By limiting nucleic‑acid production, the drug reduces the proliferation of rapidly dividing cells such as immune cells and cancer cells. This anti‑proliferative and immunosuppressive action underlies its effectiveness in autoimmune diseases and certain malignancies.

The dose of Injexate is individualized by the prescribing physician according to the specific indication, patient weight, renal function, and response to therapy. Healthcare providers calculate the appropriate amount and frequency, which may range from low weekly doses for rheumatic disease to higher, regimented doses in oncology protocols. Patients should follow the exact regimen given by their clinician.

Injexate is classified as Pregnancy Category X because it is known to cause fetal harm and birth defects. It must not be used by pregnant women or women who could become pregnant. Limited data are available for breastfeeding, and the drug is generally contraindicated because it can be excreted in milk and affect the infant. Alternative therapies should be considered.

To request Injexate, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if required—and assistance with import documentation.

Compared with other DMARDs such as leflunomide or biologic agents, methotrexate (Injexate) is often used as a first‑line oral or injectable therapy because of its long‑track record, cost‑effectiveness, and broad efficacy. Unlike biologics, it is not a protein‑based agent, so it does not require infusion centers, but it does need regular laboratory monitoring for liver and blood‑cell effects.

Injexate should be stored in a refrigerator at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If a temporary temperature excursion occurs, consult the product’s stability guidelines before use.

Injexate is supplied as a sterile solution for subcutaneous injection. A healthcare professional or trained patient can inject the prescribed dose into the fatty tissue of the abdomen or thigh using an appropriate needle. The injection site should be rotated to reduce local irritation, and aseptic technique must be followed.

The most critical risks include severe liver injury, pulmonary fibrosis, and profound bone‑marrow suppression that can lead to life‑threatening infections or bleeding. Renal toxicity and rare hypersensitivity reactions are also possible. Patients should be monitored regularly for liver enzymes, lung symptoms, blood counts, and kidney function to detect problems early.

Injexate is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe hepatic or renal impairment, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing lung disease or a history of bone‑marrow disorders. Clinicians must evaluate each patient’s medical history before initiating therapy.